Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist studied in metabolic, cardiovascular, and body composition research. Here is what the science shows.
Tirzepatide and Semaglutide are both GLP-1-based research peptides, but their mechanisms differ significantly. This comparison breaks down what makes each compound unique in research models.
Semaglutide is a GLP-1 receptor agonist studied for its role in glucose metabolism, appetite regulation, and cardiovascular research. This guide breaks down its mechanism of action.
Research peptides are short chains of amino acids used in scientific studies to explore biological processes. This guide explains what they are, how they work, and why purity matters.
Research overview of semaglutide’s cardiovascular effects beyond weight reduction — SELECT trial data, mechanisms of cardioprotection, atherosclerosis research, and emerging applications in heart failure and neurology.
Research comparison of NAD+, NMN, and NR — their roles in cellular energy metabolism, sirtuin activation, aging biology, and comparative bioavailability evidence. For educational research purposes.
Research overview of MK-677 (Ibutamoren), an orally active growth hormone secretagogue and ghrelin mimetic studied for GH release, lean mass, bone density, and metabolic research. For laboratory research use only.
Research overview of Orforglipron, Eli Lilly’s oral small-molecule GLP-1 receptor agonist studied for obesity and type 2 diabetes. Phase 3 data published in NEJM 2026. For laboratory research use only.
Research overview of Follistatin, a naturally occurring glycoprotein and endogenous myostatin/activin inhibitor studied for muscle growth, muscular dystrophy, sarcopenia, and body composition research. For laboratory research use only.
Research overview of Trevogrumab (REGN-1033), a Regeneron anti-myostatin (GDF-8) monoclonal antibody studied for muscle wasting, body composition, and GLP-1 combination research. For laboratory research use only.
